Mills, A., Richmond, G. J., Newman, C., Osiyemi, O., Cade, J., Brinson, C., De Vente, J., Andany, N., Margolis, D., Sutton, K., Wilches, V., Roberts, J., McCoig, C. C., Vandermeulen, K., & Spreen, W. (n.d.). 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study. Open forum infectious diseases, 7, S186–S187. http://access.bl.uk/ark:/81055/vdc_100121988410.0x00000d